ASTRAZEN2023-04-012023-06-30 ASTRAZEN2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member ASTRAZEN2023-04-012023-06-30in-bse-fin:OneOperatingExpenses02Member ASTRAZEN2023-04-012023-06-30in-bse-fin:OneOperatingExpenses03Member ASTRAZEN2023-06-30 ASTRAZEN2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ASTRAZEN2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 506820 ASTRAZEN NA AstraZeneca Pharma India Limited Equity 2023-04-01 2024-03-31 2023-08-14 2023-08-04 INR Lakhs First quarter 10:30:00 13:30:00 2023-08-14 2023-08-14 Not applicable Single segment Healthcare 2023-04-01 2023-06-30 Unaudited Standalone 2954668000.00 81037000.00 3035706000.00 190776000.00 1028495000.00 -113412000.00 549748000.00 1535000.00 37979000.00 626606000.00 2321727000.00 713978000.00 0.00 713978000.00 174670000.00 701000.00 175371000.00 0.00 538607000.00 0.00 0.00 0.00 0.00 538607000.00 4551000.00 543159000.00 0.00 0.00 50000000.00 2 21.54 21.54 0.00 0.00 21.54 21.54 Notes: 1 The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. 2 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly no segment information has been provided. 3 The figures for the quarter ended 31 March 2023 are the balancing figures between the audited figures in respect of the full financial year 31 March 2023 and the published unaudited year to date figures up to the third quarter of the respective financial year i.e., 31 December 2022 which were subjected to review by the statutory auditors. 4 Exceptional items for the quarter and year ended 31 March 2023 consists of seperation cost amounting to Rs.1,910.32 and Voluntary Retirement Scheme expenses amounting to Rs.2,112.59. 5 This statement of financial results was reviewed and recommended by the Audit Commiltee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 14 August 2023. The Statutory auditors of the Company have carried out a limited review of this statement of financial results for the quarter ended 30 June 2023. By Order of the Board of Directors For AstraZeneca Pharma India Limited Place: Bengaluru Sanjeev Kumar Panchal Date: 14 August, 2023 Managing Director Allowance for expected credit loss (net) -2246000.00 Other Expenses 416191000.00 Selling, marketing and distribution expense 212661000.00 Re-measurement gains/(losses) on post employment benefit obligations 6082000.00 Income tax effect on above -1531000.00 4551000.00